Immutep’s experimental drug targeting LAG-3 has failed to demonstrate efficacy in a Phase 3 clinical trial for lung cancer. The trial results, announced on...
New research from CorriXR Therapeutics has demonstrated a promising gene-editing technique that could potentially restore the effectiveness of chemotherapy in patients with aggressive cancers...